Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEmmerson Plc Regulatory News (EML)

Share Price Information for Emmerson Plc (EML)

Share Price is delayed by 15 minutes
Get Live Data
2.20    0.00 (0.00%)
Bid:
2.10
Ask:
2.30
Spread: 0.20 (9.524%)
Market Cap: £29.40m
EML Live PriceLast checked at - London Stock Exchange

Intraday Emmerson Plc Share Chart

Issue of Equity & Total Voting Rights

24 Nov 2021 07:00

RNS Number : 3231T
Emmerson PLC
24 November 2021
 

Emmerson Plc / Ticker: EML / Index: LSE / Sector: Mining

24 November 2021

 

Issue of Equity and Total Voting Rights

 

Emmerson, the Moroccan focused potash development company, announces that further to the announcement of 10 November 2021 relating to the strategic investment of up to US$46.75 million for the development of the Khemisset Potash Project, the Company has issued 81,818,182 new ordinary shares at an issue price of 6p in respect of the initial equity component of the investment representing a total of US$6.75 million (the "Subscription Shares").

 

Following the issue of the 81,818,182 Subscription Shares the Company will have a total of 915,062,661 Ordinary Shares in issue. The Company does not hold any shares in Treasury. The above figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

The above information is provided by the Company in accordance with its obligations under the FCA's Disclosure Guidance and Transparency Rules.

 

 

**ENDS**

 

For further information, please visit www.emmersonplc.com, follow us on Twitter (@emmerson_plc), or contact:

Emmerson Plc

Graham Clarke

Hayden Locke

 

Shore Capital (Nominated Adviser and Joint Broker)

Toby Gibbs / John More

 

Shard Capital (Joint Broker)

Damon Heath / Isabella Pierre

St Brides Partners (Financial PR/IR)

Susie Geliher / Isabel de Salis

 +44 (0) 20 7236 1177 

 

 

+44 (0)20 7408 4090

 

 

 

+44 (0)20 7186 9927 

 

 

+44 (0)20 7236 1177

Notes to Editors

Emmerson's primary focus is on developing the Khemisset project ("Khemisset" or the "Project") located in Northern Morocco. The Project has a large JORC Resource Estimate (2012) of 537Mt @ 9.24% K2O and significant exploration potential with an accelerated development pathway targeting a low capex, high margin mine. Khemisset is perfectly located to capitalise on the expected growth of African fertiliser consumption whilst also being located on the doorstep of European markets. This unique positioning means the Project will receive a premium netback price compared to existing potash producers. The need to feed the world's rapidly increasing population is driving demand for potash and Emmerson is well placed to benefit from the opportunities this presents. The Feasibility Study released in June 2020 indicated Khemisset has the potential to be among the lowest capital cost development stage potash projects in the world and also, as a result of its location, one of the highest margin projects. This delivered outstanding economics including a post-tax NPV8 of approximately US$1.4 billion using industry expert, Argus', price forecasts.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEEAKFDAAFFFFA
Date   Source Headline
19th Jun 20267:00 amRNSKhemisset Multi-mineral Process Patent
30th Mar 20267:00 amRNSArbitration Memorial Submission
24th Mar 20267:00 amRNSResult of WRAP Retail Offer
20th Mar 20267:31 amRNSWRAP Retail Offer for up to £100,000
20th Mar 20267:30 amRNSResult of Placing and Subscription
20th Mar 20267:00 amRNSProposed Placing and Subscription
22nd Jan 20267:00 amRNSArbitration Update
26th Nov 20257:00 amRNSAppointment of Joint Broker
30th Sep 20257:00 amRNSInterim Results
24th Jul 202512:31 pmRNSResult of Annual General Meeting
1st Jul 20257:00 amRNSNotice of AGM
30th Jun 20253:36 pmRNS2024 Financial Results
1st May 20258:10 amRNSRequest for Arbitration
17th Mar 20257:00 amRNSLitigation Funding Update
13th Jan 20253:03 pmRNSAdditional Issuance of Shares and Rights
2nd Jan 20257:00 amRNSLitigation Funding Secured
12th Dec 20247:00 amRNSAdditional Issuance of Shares and Rights
6th Dec 20247:01 amRNSFundraising of £0.85 million
1st Nov 20247:00 amRNSNotice of dispute with Moroccan Government
28th Oct 20247:00 amRNSESIA Process, Board Changes, and Cash Management
14th Oct 20247:00 amRNSESIA Update
27th Sep 20247:00 amRNSInterim Results and Q3 Update
5th Jul 20247:00 amRNSQ2 Update
1st Jul 20247:00 amRNSChange of Nominated Advisor and Joint Broker
26th Jun 202411:33 amRNSResult of Annual General Meeting
31st May 202410:56 amRNSGrant of Share Options and PDMR dealing
31st May 20247:00 amRNSNotice of AGM and Posting of Annual Report
24th May 20247:00 amRNS2023 Financial Results
22nd Apr 202411:47 amRNSTR-1: Notification of major holdings
8th Apr 20244:45 pmRNSResults of Oversubscribed REX Retail Offer
8th Apr 20247:01 amRNSREX Retail Offer
8th Apr 20247:00 amRNSQ1 Update, Equity Placing and Retail Offer
11th Mar 20247:00 amRNSCommittee Upholds Environmental Approval Referral
1st Feb 20247:00 amRNSScoping Study on Breakthrough New Processing Route
8th Jan 20247:00 amRNSQ4 Update
21st Dec 20237:00 amRNSExtension of Mandated Lead Arrangers
26th Sep 20237:00 amRNSInterim Results for the six months to 30 June 2023
21st Sep 20237:00 amRNSQ3 2023 and Financing update
11th Sep 202311:38 amRNSMorocco Statement
11th Jul 202311:57 amRNSDirector/PDMR Shareholding
10th Jul 20234:30 pmRNSDirector/PDMR Shareholding
6th Jul 20232:49 pmRNSDirector/PDMR Shareholding
6th Jul 20237:00 amRNSQ2 Update
6th Jun 20237:00 amRNSExercise & Allotment of Shares
31st May 202312:01 pmRNSResult of AGM
5th May 20237:00 amRNSNotice of AGM and Posting of Annual Report
13th Apr 20237:00 amRNS2022 Financial Results and Q1 Update
14th Feb 20237:00 amRNSMandated Lead Arrangers Appointed for Financing
9th Jan 20237:00 amRNSQ4 Update
3rd Jan 20237:00 amRNSAppointment of Liberum as Nominated Advisor

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.